Abstract
Genistein is thought to contribute to the putative breast cancer preventive activity of soya. The mechanisms by which it arrests the growth of breast cells are incompletely understood. In order to explore generic features of the modulation of human breast cell growth by genistein, its effects on cell lines MCF-7, ZR-75.1, T47-D, MDA-MB 468, MDA-MB 231 and HBL 100 were compared. Genistein at 1 μM stimulated growth only in MCF-7 cells. At 10 μM it arrested the growth of all 6 cell types, however that of T47-D and HBL 100 cells only in medium with reduced (2%) fetal calf serum. Genistein induced apoptosis in only MDA-MB 468 cells. It arrested cells in the G2 stage of the cell cycle in all cell lines except ZR-75.1. Cells differed in their susceptibility towards inhibition by genistein of phorbol ester-induced proto-oncogene c-fos levels, transcription factor activator protein-1 (AP-1) activity and extracellular signal-regulated kinase (ERK) activity. Genistein augmented anisomycin-induced levels of proto-oncogene c-jun in ZR 75.1 and MCF-7 cells. The results suggest that induction of apoptosis, G2 cell cycle arrest and inhibition of c-fos expression, AP-1 transactivation and ERK phosphorylation may contribute to the growth-inhibitory effect of genistein in some breast cell types, but none of these effects of genistein constitutes a generic mode of growth-arresting action. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adlercreutz HCT, Goldin B, Gorbach SL, Hockerstedtk AV, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT, Hase TA and Fotsis T (1995) Soybean phytoestrogen intake and cancer risk. J Nutr 125: 757S–767S
Afifi AA and Azen SP (1979) The analysis of variance. Afifi AA, Azen SP (eds) Statistical Analysis: A Computer Orientated Approach pp. 198–273, Academic Press Inc.: London
Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itck N, Shibuiya M and Fukami Y (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592–5595
Angel P and Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129–157
Bail JC, Varnat F, Nicolas JC and Habrioux G (1998) Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavanoids. Cancer Lett 130: 209–216
Balabhadrapathruni S, Thomas TJ, Yurkow EJ, Amenta PS and Thomas T (2000) Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol Reports 7: 3–12
Barnes S and Peterson TG (1995) Biochemical targets of the isoflavone genistein in tumor cell lines. Proc Soc Exp Biol Med 208: 103–107
Choi YH, Zhang L, Lee WH and Park K-Y (1998) Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol 13: 391–396
Croisy-Delcey M, Croisy A, Mousset S, Letourneur M, Bisagni E, Jacquemin-Sablon A and Pierre J (1997) Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways. Biomed Pharmacother 51: 286–294
Dampier K (2001) Studies of the mechanisms of action of the chemopreventive agent genistein. PhD thesis, University of Leicester
Dotzlaw H, Leygue E, Watson P and Murphy LC (1996) Expression of estrogen receptor-β in human breast tumors. J Clin Endocrinol Metab 82: 2371–2374
Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M and Gustafsson J (1997) Human estrogen receptor-β gene structure, chromosomal localization and expression pattern. J Clin Endocrinol Metab 82: 4258–4265
Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M and Di Fronzo G (1998) Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Lett 130: 143–152
Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R and Schweigerer L (1993) Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90: 2690–2694
Germain M, Affar E-B, D'Amours D, Dixit VM, Salveseni GS and Poirier GG (1999) Cleavage of automodified poly (ADP-ribose) polymerase during apoptosis. J Biol Chem 274: 28379–28384
Hsieh C, Santell RC, Haslam SZ and Helferich WG (1998) Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 58: 3833–3838
Karin M (1996) The regulation of AP-1 activity by mitogen-activated protein kinases. Philos Trans R Soc Lond B 351: 127–134
Kaufmann WK (1998) Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 217: 327–334
Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S and Gustafsson J-A (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138: 863–870
Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, Saag PT, Burg B and Gustafsson J-A (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139: 4252–4263
Lamartiniere CA, Moore J, Holland M and Barnes S (1995) Neonatal genistein chemoprevents mammary cancer. Proc Soc Exp Biol Med 208: 120–123
Leppa S and Bohnmann D (1999) Diverse functions of JNK signalling and c-jun in stress response and apoptosis. Oncogene 18: 6158–6162
Li Y, Upadhyay S, Bhuiyan M and Sarkar FH (1999) Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18: 3166–3172
MacFarlane M, Cain K, Sun X, Alnemri ES and Cohen GM (1997) Processing/activation of at least four interleukin 1 β-converting enzyme-like proteases during the execution phase of apoptosis in human monocytic tumor cells. J Cell Biol 137: 469–479
Messina MJ, Persky V, Setchell KDR and Barnes S (1994) Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21: 113–127
Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA (1999) Upregulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528–21532
Peterson G (1995) Evaluation of the biochemical targets of genistein in tumor cells. J Nutr 125: 784S–788S
Rickwood D and Hames BD (1990) Flow Cytometry. A Practical Approach 75 Oxford University Press: Oxford
Sambrook J, Fritsch EF and Maniatis T (1989) SDS-Polyacrylamide gel electrophoresis of proteins. Sambrook J, Fritsch EF, Maniatis T (eds) Molecular Cloning: A Laboratory Manual pp. 18–47, Harbor Laboratory Press: Cold Spring
Schultze-Mosgau M-H, Dale IL, Gant TW, Chipman JK, Kerr DJ and Gescher A (1998) Regulation of c-fos transcription by chemopreventative isoflavanoids and lignans in MDA-MB 468 breast cancer cells. Eur J Cancer 34: 1425–1431
Shao Z-M, Alpaugh ML, Fontana JA and Barsky SH (1998) Genistein inhibits proliferation similarly in estrogen receptor positive and negative human breast carcinoma cell lines, characterised by p21WAF1/CIP1induction, G2/M arrest and apoptosis. J Cell Biochem 69: 44–54
Smith LM, Birrer MJ, Stampfer MR and Brown PH (1997) Breast cancer cells have lower activating protein-1 transcription factor activity than normal mammary epithelial cells. Cancer Res 57: 3046–3054
Snedecor GW and Cochran WG (1980) Analysis of variance. Snedecor GW, Cochran WG (eds). Statistical Methods pp. 215–237, Iowa State University Press: Ames
Wang Y, Zhang X, Lebwohl M, Deleo V and Wei H (1998) Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis 19: 649–654
Wei H, Barnes S and Wang Y (1996) Inhibitory effect of genistein on a tumor promoter-induced c-fos and c-jun expression in mouse skin. Oncol Reports 3: 125–128
Zava DT and Duwe G (1997) Estrogenic and antiproliferative properties of genistein and other flavanoids in human breast cancer cells in vitro. Nutr Cancer 27: 31–40
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Dampier, K., Hudson, E., Howells, L. et al. Differences between human breast cell lines in susceptibility towards growth inhibition by genistein. Br J Cancer 85, 618–624 (2001). https://doi.org/10.1054/bjoc.2001.1980
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1980
Keywords
This article is cited by
-
Inhibition of Neu-Induced Mammary Carcinogenesis in Transgenic Mice Expressing ERΔ3, a Dominant Negative Estrogen Receptor α Variant
Hormones and Cancer (2012)
-
The effects of different lignans and isoflavones, tested as aglycones and glycosides, on hormone receptor-positive and -negative breast carcinoma cells in vitro
Archives of Gynecology and Obstetrics (2011)
-
The molecular basis of genistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines
BMC Medical Genomics (2008)
-
Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells
Cell Biology and Toxicology (2008)
-
Phyto-oestrogens and breast cancer chemoprevention
Breast Cancer Research (2004)
